Blab AI
Butterfly Network Raises 2026 Guidance Amid Strong Q2 Results, Highlights AI-Powered Ultrasound Growth
Butterfly Network Inc. (NYSE: BFLY) reported record revenue for fiscal Q2 2026, prompting a lift in its full‑year guidance and a rally in the stock. The company posted $32.6 million in revenue, a 39 % year‑over‑year increase that surpassed analyst expectations. According to the company’s earnings release, the adjusted earnings‑per‑share loss narrowed to –$0.01, well below the consensus estimate of –$0.037.
The company reiterated its 2026 revenue forecast of $119 million to $123 million, a range that aligns with the $117 million to $121 million guidance issued in Q1. Butterfly Network’s revenue mix remains heavily weighted toward the United States, where it earned roughly $92 million, with an additional $20 million from international markets. The company’s market capitalization is approximately $2.0 billion.
Butterfly Network’s core product is a handheld ultrasound probe that plugs into a smartphone or tablet. The probe is paired with the company’s Compass AI enterprise software and the ScanLab educational app. Compass AI automates documentation, quality assurance and workflow management for point‑of‑care ultrasound (POCUS) programs in hospitals and health systems. ScanLab, available only on iPad, provides clinicians and students with AI‑driven training videos and interactive practice.
The company’s recent product launches underscore its strategy to combine hardware with software. In November 2025, Butterfly Network announced the launch of Compass AI, describing it as an “AI‑powered operating system built for compliant, scalable, revenue‑ready POCUS programs.” The company has also entered agreements around ultrasound‑on‑chip technology and AI‑enabled brain‑computer interface applications, which could open new revenue streams but also add execution risk.
Despite the revenue growth, Butterfly Network remains loss‑making. The company’s adjusted EBITDA loss for 2026 is projected to be between $21 million and $25 million. Investors and analysts note that the firm’s funding and governance structure warrant close attention. According to publicly available data, Butterfly Network has raised a total of $350 million across four funding rounds from 15 investors, including Fidelity Investments and Stanford University. The most recent round was a $5 million infusion in March 2022.
The company’s financial performance and guidance have attracted attention from small‑cap investors looking for AI‑driven growth stories outside the large‑cap space. Analysts point out that the combination of a portable hardware platform and AI‑enabled software gives Butterfly Network a unique position in the medical imaging market, which is traditionally dominated by large, expensive machines.
In the broader context, the company’s focus on point‑of‑care ultrasound aligns with a growing trend toward mobile, AI‑assisted diagnostics. The handheld probe can be used in a variety of settings, from bedside care to field operations, potentially expanding access to imaging in underserved regions.
Key takeaways for investors and industry observers are:
Butterfly Network’s Q2 revenue beat expectations, and the company has raised its 2026 guidance. The company’s Compass AI and ScanLab software layers differentiate it from other handheld ultrasound vendors. The firm remains loss‑making and relies on external capital; its governance and funding structure are under scrutiny. New partnerships in ultrasound‑on‑chip and brain‑computer interface technology could broaden the company’s product portfolio.
As the company continues to scale its hardware and software offerings, the next quarter’s earnings will be closely watched for any changes in revenue mix, profitability, or capital needs. The market will also monitor how Butterfly Network navigates regulatory approvals for its AI‑driven imaging solutions and how it positions itself against competitors in the rapidly evolving point‑of‑care ultrasound space.
Overall, Butterfly Network’s recent financial results and guidance suggest that the company is gaining traction, but its long‑term viability will depend on its ability to convert hardware sales into profitable software‑driven services while securing sufficient capital to support continued growth.
The company reiterated its 2026 revenue forecast of $119 million to $123 million, a range that aligns with the $117 million to $121 million guidance issued in Q1. Butterfly Network’s revenue mix remains heavily weighted toward the United States, where it earned roughly $92 million, with an additional $20 million from international markets. The company’s market capitalization is approximately $2.0 billion.
Butterfly Network’s core product is a handheld ultrasound probe that plugs into a smartphone or tablet. The probe is paired with the company’s Compass AI enterprise software and the ScanLab educational app. Compass AI automates documentation, quality assurance and workflow management for point‑of‑care ultrasound (POCUS) programs in hospitals and health systems. ScanLab, available only on iPad, provides clinicians and students with AI‑driven training videos and interactive practice.
The company’s recent product launches underscore its strategy to combine hardware with software. In November 2025, Butterfly Network announced the launch of Compass AI, describing it as an “AI‑powered operating system built for compliant, scalable, revenue‑ready POCUS programs.” The company has also entered agreements around ultrasound‑on‑chip technology and AI‑enabled brain‑computer interface applications, which could open new revenue streams but also add execution risk.
Despite the revenue growth, Butterfly Network remains loss‑making. The company’s adjusted EBITDA loss for 2026 is projected to be between $21 million and $25 million. Investors and analysts note that the firm’s funding and governance structure warrant close attention. According to publicly available data, Butterfly Network has raised a total of $350 million across four funding rounds from 15 investors, including Fidelity Investments and Stanford University. The most recent round was a $5 million infusion in March 2022.
The company’s financial performance and guidance have attracted attention from small‑cap investors looking for AI‑driven growth stories outside the large‑cap space. Analysts point out that the combination of a portable hardware platform and AI‑enabled software gives Butterfly Network a unique position in the medical imaging market, which is traditionally dominated by large, expensive machines.
In the broader context, the company’s focus on point‑of‑care ultrasound aligns with a growing trend toward mobile, AI‑assisted diagnostics. The handheld probe can be used in a variety of settings, from bedside care to field operations, potentially expanding access to imaging in underserved regions.
Key takeaways for investors and industry observers are:
Butterfly Network’s Q2 revenue beat expectations, and the company has raised its 2026 guidance. The company’s Compass AI and ScanLab software layers differentiate it from other handheld ultrasound vendors. The firm remains loss‑making and relies on external capital; its governance and funding structure are under scrutiny. New partnerships in ultrasound‑on‑chip and brain‑computer interface technology could broaden the company’s product portfolio.
As the company continues to scale its hardware and software offerings, the next quarter’s earnings will be closely watched for any changes in revenue mix, profitability, or capital needs. The market will also monitor how Butterfly Network navigates regulatory approvals for its AI‑driven imaging solutions and how it positions itself against competitors in the rapidly evolving point‑of‑care ultrasound space.
Overall, Butterfly Network’s recent financial results and guidance suggest that the company is gaining traction, but its long‑term viability will depend on its ability to convert hardware sales into profitable software‑driven services while securing sufficient capital to support continued growth.
